# Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

> **NCT04305496** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 818 (actual)

## Conditions studied

- Locally Advanced (Inoperable) or Metastatic Breast Cancer

## Interventions

- **DRUG:** Fulvestrant
- **DRUG:** Capivasertib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04305496
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-04-16
- **Primary completion:** 2023-05-09
- **Final completion:** 2026-06-22
- **Target enrollment:** 818 (ACTUAL)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04305496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04305496, "Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04305496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*